Toward improving therapeutic regimens for bacillus endophthalmitis

Investigative Ophthalmology and Visual Science

Volumn 49, Issue 4, 2008, Pages 1480-1487

  Wiskur, Brandt J ^a   Robinson, Michael L ^b   Farrand, Allison J ^b   Novosad, Billy D ^b,c   Callegan, Michelle C ^b,c  

^a UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

^b UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; GATIFLOXACIN; VANCOMYCIN; ANTIINFECTIVE AGENT; GLUCOCORTICOID; QUINOLONE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACILLUS CEREUS; CONTROLLED STUDY; DRUG PENETRATION; ELECTRORETINOGRAPHY; ENDOPHTHALMITIS; HISTOPATHOLOGY; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; NONHUMAN; PIGMENT EPITHELIUM; PRIORITY JOURNAL; RABBIT; ANIMAL; BACTERIAL EYE INFECTION; BACTERIAL INFECTION; BIOAVAILABILITY; COMPARATIVE STUDY; DISEASE MODEL; DRUG COMBINATION; DRUG EFFECT; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; PHYSIOLOGY; RETINA; VITREOUS BODY;

ANIMALS; ANTI-BACTERIAL AGENTS; BACILLUS CEREUS; BIOLOGICAL AVAILABILITY; DEXAMETHASONE; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; ELECTRORETINOGRAPHY; ENDOPHTHALMITIS; EYE INFECTIONS, BACTERIAL; FLUOROQUINOLONES; GLUCOCORTICOIDS; GRAM-POSITIVE BACTERIAL INFECTIONS; MICROBIAL SENSITIVITY TESTS; RABBITS; RETINA; VANCOMYCIN; VITREOUS BODY;

EID: 45549092474     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.07-1303     Document Type: Article

References (45)

1. Thompson, ST, Parver LM, Enger CL, Meiler WF, Ligget PE. Infectious endophthalmitis after penetrating injuries with retained intraocular foreign bodies. Ophthalmology. 1993;100:1468-1474.
2. Meredith TA. Posttraumatic endophthalmitis. Arch Ophthalmol. 1999;117:520-521.
3. Chhabra S, Kunimoto DY, Kazi L, et al. Endophthalmitis after open globe injury: microbiologic spectrum and susceptibilities of isolates. Am J Ophthalmol. 2007;142:852-854.
4. David DB, Kirkby GR, Noble BA. Bacillus cereus endophthalmitis. Br J Ophthalmol. 1994;78:577-580.
5. Davey RJ, Tauber WB. Posttraumatic endophthalmitis: the emerging role of Bacillus cereus infection. Rev Infect Dis. 1987;9:110-123.
6. O'Day DM, Smith RS, Gregg CR, et al. The problem of Bacillus species infection with special emphasis on the virulence of Bacillus cereus. Ophthalmology. 1981;88:833-838.
7. Benz MS, Scott IU, Flynn HW Jr, Unonius N, Miller D. Endoph-thalmitis isolates and antibiotic sensitivities: a 6-year review of culture-proven cases. Am J Ophthalmol. 2004;137:38- 42.
8. 8.Recchia FM, Busbee BG, Pearlman RB, Carvalho-Recchia CA, Ho AC. Changing trends in microbiology of postcataract endoph-thalmitis. Arch Ophthalmol. 2005;123:341-346.
9. Callegan MQ Cochran DC, Kane ST, et al. Virulence factor profiles and antimicrobial susceptibilities of ocular Bacillus isolates. Curr Eye Res. 2006;31:693-702.
10. Hariprasad SM, Mieler WF, Holz ER. Vitreous and aqueous penetration of orally administered gatifloxacin in humans. Arch Oph-thalmol. 2003;121:345-350.
11. Luna VA, King DS, Gulledge J, et al. Susceptibility of Bacillus anthracis, Bacillus cereus, Bacillus mycoides, Bacillus pseudo-mycoides and Bacillus thuringiensis to 24 antimicrobials using Sensititre automated microbroth dilution and E-test agar gradient diffusion methods. JAntimicrob Chemother. 2007;60:555-567.
12. Das T, Jalali S, Grothwal VK, Sharma S, Naduvilath TJ. Intravitreal dexamethasone in exogenous bacterial endophthalmitis: results of a prospective randomized study. Br J Ophthalmol. 1999;83:1050 -1055.
13. Gan IM, Ugarhary LC, van Dissel JT, et al. Intravitreal dexametha-sone as adjuvant in the treatment of postoperative endoph-thalmitis: a prospective randomized trial. Graefe,s Arch Clin Exp Ophthalmol. 2005;243:1200-1205.
14. Shah GK, Stein JD, Sharma S, et al. Visual outcomes following the use of intravitreal steroids in the treatment of postoperative en-dophthalmitis. Ophthalmology. 2000;107:486- 489.
15. Meredith TA, Aguilar HE, Drews C, et al. Intraocular dexametha-sone produces a harmful effect on treatment of experimental Staphylococcus aureus endophthalmitis. Trans Am Ophthalmol Soc. 1996;94:241-257.
16. Liu SM, Way T, Rodrigues M, Steidl SM. Effects of intravitreal corticosteroids in the treatment of Bacillus cereus endophthalmi-tis. Arch Ophthalmol. 2000;118:803-806.
17. Park SS, Samiy N, Ruoff K, D-Amico DJ, Baker AS. Effect of intra-vitreal dexamethasone in treatment of pneumococcal endoph-thalmitis in rabbits. Arch Ophthalmol. 1995;113:1324-1329.
18. Smith MA, Sorenson JA, D,Aversa G, et al. Treatment of experimental methicillin-resistant Staphylococcus epidermidis endoph-thalmitis with intravitreal vancomycin and intravitreal dexameth-asone. J Infect Dis. 1997;175:462-466.
19. Yildirim O, Oz O, Aslan G, et al. The efficacy of intravitreal levofloxacin and intravitreal dexamethasone in experimental Staphylococcus epidermidis endophthalmitis. Ophthalmic Res. 2002;34:349-356.
20. Yoshizumi MO, Lee GC, Equi RA, et al. Timing of dexamethasone treatment in experimental Staphylococcus aureus endophthalmi-tis. Retina. 1998;18:130-135.
21. Ermis SS, Cetinkaya Z, Kiyici H, Ozturk F. Treatment of Staphylococcus epidermidis endophthalmitis with intravitreal moxifloxa-cin in a rabbit model. Tohoku J Exp Med. 2005;205:223-229.
22. Kim IT, Chung KH, Koo BS. Efficacy of ciprofloxacin and dexamethasone in experimental Pseudomonas endophthalmitis. Korean J Ophthalmol. 1996;10:8-17.
23. Pollack JS, Beecher DJ, Pulido JS, Lee Wong AC. Failure of intra-vitreal dexamethasone to diminish inflammation or retinal toxicity in an experimental model of Bacillus cereus endophthalmitis. Curr Eye Res. 2004;29:253-259.
24. Callegan MC, Jett BD, Hancock LE, Gilmore MS. Role of hemolysin BL in the pathogenesis of extraintestinal Bacillus cereus infection as assessed using an endophthalmitis model. Infect Immun. 1999; 67:3357-3366.
25. Callegan MC, Booth MC, Jett BD, Gilmore MS. Pathogenesis of Gram-positive bacterial endophthalmitis. Infect Immun. 1999;67: 3348-3356.
26. Callegan MC, Cochran DC, Kane ST, et al. Contribution of membrane-damaging toxins to Bacillus endophthalmitis pathogenesis. Infect Immun. 2002;70:5381-5389.
27. Callegan MC, Kane ST, Chochran DC, et al. Relationship of plcR-regulated factors to Bacillus endophthalmitis virulence. Infect Immun. 2003;71:3116-3124.
28. Ramadan RT, Ramirez R, Novosad BD, Callegan MC. Acute inflammation and loss of retinal architecture and function during experimental Bacillus endophthalmitis. Curr Eye Res. 2006;31:955-965.
29. Sheehan DC, Hrapchak. Theory and Practice of Histotechnology. Columbus, Ohio: Batelle Press; 1987.
30. Engel LS, Callegan MC, Hill JM, O'Callaghan RJ. Bioassays for quantitating ciprofloxacin and tobramycin in aqueous humor. J Ocular Pharmacol. 1993;9:311-320.
31. Limb GA, Salt TE, Munro PM, Moss SE, Khaw PT. In vitro characterization of a spontaneously immortalized human Müller cell line (MIO-M1). Invest Ophthalmol Vis Sci. 2002;43:864-869.
32. Tan E, Ding XQ, Saadi A, et al. Expression of cone-photoreceptor- specific antigens in a cell line derived from retinal tumors in transgenic mice. Invest Ophthalmol Vis Sci. 2004;45:764-768.
33. Alfaro DV, Davis J, Kim S, et al. Experimental Bacillus cereus posttraumatic endophthalmitis and treatment with ciprofloxacin. Br J Ophthalmol. 1996;80:755-758.
34. Alfaro DV, Hudson SJ, Steele JJ, et al. Experimental posttraumatic Bacillus cereus endophthalmitis in a swine model: efficacy of intravitreal ciprofloxacin, vancomycin, and imipenem. Retina. 1996;16:317-323.
35. Gan IM, Ugarhary LC, van Dissel JT, et al. Effect of intravitreal dexamethasone on vitreous vancomycin concentrations in patients with suspected postoperative bacterial endophthalmitis. Graefe's Arch Clin Exp Ophthalmol. 2005;243:1186-1189.
36. Callegan MC, Kane ST, Cochran DC, Gilmore MS. Molecular mechanisms of Bacillus endophthalmitis pathogenesis. DNA Cell Biol. 2002;21:367-373.
37. Smith MA, Sorenson JA, Smith C, Miller M, Borenstein M. Effects of intravitreal dexamethasone on concentration of intravitreal vanco- mycin in experimental methicillin-resistant Staphylococcus epider- midis endophthalmitis. Antimicrob Agents Chemother. 1991;35: 1298-1302.
38. Park SS, Vallar RV, Hong CH, et al. Intravitreal dexamethasone effect on intravitreal vancomycin elimination in endophthalmitis. Arch Ophthalmol. 1999;117:1058-1062.
39. Hui M, Kwok A, Pang CP, et al. An in vitro study on the compatibility and concentrations of combinations of vancomycin, amika- cin, and dexamethasone in human vitreous. Eye. 2007;21:643-648.
40. Campochiaro PA, Lim JI. Aminoglycoside toxicity in the treatment of endophthalmitis: the Aminoglycoside Toxicity Study Group. Arch Ophthalmol. 1994;112:48-53.
41. Jackson TL, Williamson TH. Amikacin retinal toxicity. Br J Oph- thalmol. 1999;83:1199-2000.
42. Wiechens B, Neumann D, Grammer JB, et al. Retinal toxicity of liposome-incorporated and free ofloxacin after intravitreal injection in rabbit eyes. Int Ophthalmol. 1998-1999;22:133-143.
43. Stevens SX, Fouraker BD, Jensen HG. Intraocular safety of cipro- floxacin. Arch Ophthalmol. 1991;109:1737-1743.
44. Ermis SS, Cetinkaya Z, Kiyici H, Inan UU, Ozturk F. Effects of intravitreal moxifloxacin and dexamethasone in experimental Staphylococcs aureus endophthalmitis. Curr Eye Res. 2007;32: 337-334.
45. Das T, Choudhury K, Sharma S, et al. Clinical profile and outcome in Bacillus endophthalmitis. Ophthalmology. 2001;108:1819-1825.